The research company Peptonic Medical has sent the first delivery within the framework of its partner agreement in the US, marking the transition from the preparation phase to commercial deliveries. The agreement covers the US, Canada, Mexico and the UK, where the products are sold under the partner’s own brand.The first order was received in October 2025 and amounts to approximately SEK 1.1 million. According to acting CEO Daniel Rudeklint, the delivery confirms the company’s ability to turn international partnerships into commercial operations and creates conditions for continued growth in the markets covered by the agreement.